| NCT ID | NCT07161882 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Société Algérienne de Formation et de Recherche en Oncologie |
| Condition | Lung Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,750 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,750 participants in total. It began in 2025-06-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors. Eligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required. The study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS). The findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor) * Diagnosed at the time of inclusion or within the 12 previous months * Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals * Signed informed consent obtained Exclusion Criteria: * Prior enrollment in this study * Participation in an interventional clinical trial
Contact & Investigator
Adda BOUNEDJAR, Professor of Medical Oncology
PRINCIPAL INVESTIGATOR
Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria
Frequently Asked Questions
Who can join the NCT07161882 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07161882 currently recruiting?
Yes, NCT07161882 is actively recruiting participants. Contact the research team at l.issiakhem@cmsolutionsdz.com for enrollment information.
Where is the NCT07161882 trial being conducted?
This trial is being conducted at Algiers, Algeria, Algiers, Algeria, Algiers, Algeria, Algiers, Algeria and 11 additional locations.
Who is sponsoring the NCT07161882 clinical trial?
NCT07161882 is sponsored by Société Algérienne de Formation et de Recherche en Oncologie. The principal investigator is Adda BOUNEDJAR, Professor of Medical Oncology at Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria. The trial plans to enroll 3,750 participants.